Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORE LABORATORIES N VCLB · Entity 11862 | Director · Chairman and CEO | February 16, 2023 | February 21, 2023 |
| Core Laboratories Inc. /DE/CLB · Entity 5382 | Director · Chairman and CEO | July 31, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORE LABORATORIES N V
Report date February 16, 2023 · Filed February 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 155,126 |
Reported balance
After 2023-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-16 · Grant · Acquired 155,126 · Balance 155,126 F1: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. |
Filing footnotes · ownership attribution and instrument terms
F1: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period.
F2: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.
Core Laboratories Inc. /DE/
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,438 |
Reported balance
After 2026-07-31 transaction · row 1
1 source rowRow 1 · 2026-07-31 · Purchase · Acquired 5,000 · Balance 262,438 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 14:40 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | PurchaseCommon Stock | 5,000 | $10.78 | $53,900.00 |
DisclosureSEC source: 0001193125-26-331852 · ownership.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,438 Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 16:02 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | GrantPerformance Shares · Derivative | 204,340 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-053588 · ownership.xml · derivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,340 Underlying: Common Stock · 204,340 shares Expires not disclosed F1 · derivative.exercise_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:16 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionPerformance Shares · Derivative | 180,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-002248 · ownership.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 180,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:16 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 180,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-002248 · ownership.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:16 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 112,681 | $16.03 | $1,806,276.43 |
DisclosureSEC source: 0001193125-26-002248 · ownership.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,438 Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 21:35 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | GrantPerformance Shares · Derivative | 202,764 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-019957 · ownership.xml · derivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,764 Underlying: Common Stock · 202,764 shares Expires not disclosed F1 · derivative.exercise_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on January 1, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests following the conclusion of a three-year performance period that began on January 1, 2025 and ends on December 31, 2027 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on January 1, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:00 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionPerformance Shares · Derivative | 69,574 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-001332 · ownership.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,574 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:00 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 69,574 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-001332 · ownership.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:00 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 43,380 | $17.31 | $750,907.80 |
DisclosureSEC source: 0000950170-25-001332 · ownership.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,397 Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 21:12 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | GrantPerformance Shares · Derivative | 234,124 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015891 · ownership.xml · derivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,124 Underlying: Common Stock · 234,124 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:40 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionPerformance Shares · Derivative | 100,058 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001227 · ownership.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021. The Company finished in the 81st percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2023. Excess shares that could vest above the 75th percentile are subject to an absolute total shareholder return modifier, which was negative over the relevant performance period, thereby reducing the number of such shares eligible to vest by one-half. Therefore, the performance criteria and requirements for vesting have been satisfied at 106.25% of the target award level, and such number of shares vested on December 31, 2023. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021. The Company finished in the 81st percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2023. Excess shares that could vest above the 75th percentile are subject to an absolute total shareholder return modifier, which was negative over the relevant performance period, thereby reducing the number of such shares eligible to vest by one-half. Therefore, the performance criteria and requirements for vesting have been satisfied at 106.25% of the target award level, and such number of shares vested on December 31, 2023. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:40 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 100,058 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001227 · ownership.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:40 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 38,473 | $17.66 | $679,433.18 |
DisclosureSEC source: 0000950170-24-001227 · ownership.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,103 Read SEC document |
| December 31, 2023 Filed Jan 8, 2024 19:41 UTC Amendment | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 39,373 | $17.66 | $695,327.18 |
DisclosureSEC source: 0000950170-24-002882 · ownership.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,203 F1 · shares: The original Form 4, filed on January 3, 2024, is being amended by this Form 4 amendment to correct an administrative error of the issuer, whereupon the number of shares withheld to satisfy tax withholding obligations upon vesting of certain restricted performance shares was misreported as 38,473 shares. The corrected transaction reflects an increase of 900 shares withheld by the issuer as a result such vesting and a corresponding reduction in the number of shares beneficially owned by the reporting person. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 15:12 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 155,126 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011093 · doc4.xml · derivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,126 Underlying: Common Shares · 155,126 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.expiration_date: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 16:46 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionPerformance Shares · Derivative | 91,212 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001001 · doc4.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 91,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2020, as disclosed in the Reporting Person's Form 4 filing on February 12, 2020. All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2022 at the conclusion of the performance period. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2020, as disclosed in the Reporting Person's Form 4 filing on February 12, 2020. All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2022 at the conclusion of the performance period. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 16:46 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 91,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001001 · doc4.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 16:46 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 35,892 | $20.27 | $727,530.84 |
DisclosureSEC source: 0001209191-23-001001 · doc4.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,518 Read SEC document |
| February 17, 2022 Filed Feb 17, 2022 17:07 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 127,424 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010858 · doc4.xml · derivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,424 Underlying: Common Shares · 127,424 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2022 and ends on December 31, 2024 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause, termination by the employee for "good reason" (as defined in the employee's employment agreement), or retirement by the employee upon having reached 62 years of age. The shares would vest, if at all, at the end of the Performance Period as follows: (i) 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group ("BPG"); (ii) 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG; or (iii) 150% of the award will vest if the Company is the top performing ROIC company of the BPG, all as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Share Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2022 and ends on December 31, 2024 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause, termination by the employee for "good reason" (as defined in the employee's employment agreement), or retirement by the employee upon having reached 62 years of age. The shares would vest, if at all, at the end of the Performance Period as follows: (i) 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group ("BPG"); (ii) 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG; or (iii) 150% of the award will vest if the Company is the top performing ROIC company of the BPG, all as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.expiration_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Share Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:52 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionPerformance Shares · Derivative | 46,233 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001059 · doc4.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 46,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vesting were awarded as restricted performance shares in February 2019 as reported in the Form 4 filing on February 14, 2019. This filing states that 50% of the restricted performance shares will vest at the end of the Performance Period if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th ROIC percentile of the BPG and 150% of the award will vest if the Company is the top performing company of the BPG. The Company was the top performing ROIC company as of the end of the performance period and as such the performance criteria and all requirements for full vesting have been met and thus the shares granted in February 2019 vested on December 31, 2021, at the conclusion of the performance period. F1 · derivative.expiration_date: The shares vesting were awarded as restricted performance shares in February 2019 as reported in the Form 4 filing on February 14, 2019. This filing states that 50% of the restricted performance shares will vest at the end of the Performance Period if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th ROIC percentile of the BPG and 150% of the award will vest if the Company is the top performing company of the BPG. The Company was the top performing ROIC company as of the end of the performance period and as such the performance criteria and all requirements for full vesting have been met and thus the shares granted in February 2019 vested on December 31, 2021, at the conclusion of the performance period. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:52 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 46,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001059 · doc4.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:52 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 18,193 | $22.31 | $405,885.83 |
DisclosureSEC source: 0001209191-22-001059 · doc4.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,198 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 16:41 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 94,172 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013239 · doc4.xml · derivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,172 Underlying: Common Shares · 94,172 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2021 and ends on December 31, 2023 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG all as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.exercise_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2021 and ends on December 31, 2023 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG all as measured and determined by the Compensation Committee at the end of the Performance Period. F2 · derivative.expiration_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionPerformance Shares · Derivative | 13,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001035 · doc4.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vesting were awarded as restricted performance shares in February 2018 as reported in the Form 4 filing on February 13, 2018. This filing states that 50% of the restricted performance shares will vest at the end of the Performance Period if the Company is in the top 50th ROIC percentile among a Bloomberg Peer Group(BPG), 100% of the award will vest if the Company is in the top 75th ROIC percentile of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG. The Company was in the top 75th the top performing ROIC percentile company as of the end of the performance period and as such the performance criteria and all requirements for 100% vesting have been met and thus the shares granted in February 2018 vested on December 31, 2020, at the conclusion of the performance period. F1 · derivative.expiration_date: The shares vesting were awarded as restricted performance shares in February 2018 as reported in the Form 4 filing on February 13, 2018. This filing states that 50% of the restricted performance shares will vest at the end of the Performance Period if the Company is in the top 50th ROIC percentile among a Bloomberg Peer Group(BPG), 100% of the award will vest if the Company is in the top 75th ROIC percentile of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG. The Company was in the top 75th the top performing ROIC percentile company as of the end of the performance period and as such the performance criteria and all requirements for 100% vesting have been met and thus the shares granted in February 2018 vested on December 31, 2020, at the conclusion of the performance period. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 5,384 | $26.51 | $142,729.84 |
DisclosureSEC source: 0001209191-21-001035 · doc4.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,158 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 13,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001035 · doc4.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:52 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022437 · doc4.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:52 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 39 | $9.49 | $370.11 |
DisclosureSEC source: 0001209191-20-022437 · doc4.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,860 Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:52 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022437 · doc4.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:18 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 91,212 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008876 · doc4.xml · derivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,212 Underlying: Common Shares · 91,212 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2020 and ends on December 31, 2022 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG. F2 · derivative.exercise_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the 2020 Performance Period is negative, all as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If the minimum performance criteria is not met, then no shares shall vest and the award shall be forfeited. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2020 and ends on December 31, 2022 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing ROIC company of the BPG. F2 · derivative.expiration_date: These awards will be interpolated on a straight-line basis from the 50th percentile to the 100th percentile. The amount that vests over the 100% of the award up to the maximum 150% of the award, if any, is subject to a reduction of one-half of the final percentage above 100% if absolute Total Shareholder Return for the 2020 Performance Period is negative, all as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If the minimum performance criteria is not met, then no shares shall vest and the award shall be forfeited. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 10:57 UTC | CORE LABORATORIES N V CLB · Entity 11862 | PurchaseCommon Shares | 1,000 | $34.60 | $34,600.00 |
DisclosureSEC source: 0001209191-20-006188 · doc4.xml · nonDerivative · entry 3 Bruno Lawrence · CIK 0001730336 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,799 Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 10:57 UTC | CORE LABORATORIES N V CLB · Entity 11862 | PurchaseCommon Shares | 1,000 | $34.98 | $34,979.00 |
DisclosureSEC source: 0001209191-20-006188 · doc4.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,799 Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 10:57 UTC | CORE LABORATORIES N V CLB · Entity 11862 | PurchaseCommon Shares | 1,000 | $35.00 | $35,000.00 |
DisclosureSEC source: 0001209191-20-006188 · doc4.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,799 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionPerformance Shares · Derivative | 2,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000796 · doc4.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These awards vested at the end of a three-year performance period that began on January 1, 2017 and ended December 31, 2019 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. F1 · derivative.expiration_date: These awards vested at the end of a three-year performance period that began on January 1, 2017 and ended December 31, 2019 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 945 | $37.67 | $35,598.15 |
DisclosureSEC source: 0001209191-20-000796 · doc4.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,799 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000796 · doc4.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000047 · wf-form4_155423571514310.xml · derivative · entry 4 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Underlying: Common Shares · 100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 46 | $68.93 | $3,170.78 |
DisclosureSEC source: 0001000229-19-000047 · wf-form4_155423571514310.xml · nonDerivative · entry 3 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,344 Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000047 · wf-form4_155423571514310.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantCommon Shares | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000047 · wf-form4_155423571514310.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,290 F1 · security: Common shares owned were inadvertently overstated by 100 shares in the initial Form 3 filed. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 16:28 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 30,822 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000027 · wf-form4_155017971299525.xml · derivative · entry 1 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,822 Underlying: Common Shares · 30,822 shares Expires not disclosed F1 · derivative.exercise_date: This award vests at the end of a three-year performance period that began on January 1, 2019 and ends on December 31, 2021 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing company of the BPG, all as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If the minimum performance criteria is not met, then no shares shall vest and the award shall be forfeited. F1 · derivative.expiration_date: This award vests at the end of a three-year performance period that began on January 1, 2019 and ends on December 31, 2021 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 64 years of age. In all cases, the shares will vest at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 50th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 75th percentile of ROIC of the BPG and 150% of the award will vest if the Company is the top performing company of the BPG, all as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If the minimum performance criteria is not met, then no shares shall vest and the award shall be forfeited. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 16:20 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionPerformance Shares · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000008 · wf-form4_154655035655697.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These awards vested at the end of a three-year performance period that began on January 1, 2016 and ended on December 31, 2018 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. F1 · derivative.expiration_date: These awards vested at the end of a three-year performance period that began on January 1, 2016 and ended on December 31, 2018 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 16:20 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 1,181 | $59.66 | $70,458.46 |
DisclosureSEC source: 0001000229-19-000008 · wf-form4_154655035655697.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,390 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 16:20 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000008 · wf-form4_154655035655697.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2018 Filed Sep 4, 2018 17:56 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000104 · wf-form4_153609817076710.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Underlying: Common Shares · 100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Multiple restricted share grants are included in this total. F2 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: Multiple restricted share grants are included in this total. F2 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document |
| September 01, 2018 Filed Sep 4, 2018 17:56 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 39 | $114.55 | $4,467.45 |
DisclosureSEC source: 0001000229-18-000104 · wf-form4_153609817076710.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,571 Read SEC document |
| September 01, 2018 Filed Sep 4, 2018 17:56 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000104 · wf-form4_153609817076710.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 16:29 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000100 · wf-form4_153332814950530.xml · derivative · entry 3 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Shares · 200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Multiple restricted share grants are included in this total. F2 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: Multiple restricted share grants are included in this total. F2 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 16:29 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 47 | $111.91 | $5,259.77 |
DisclosureSEC source: 0001000229-18-000100 · wf-form4_153332814950530.xml · nonDerivative · entry 2 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,510 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 16:29 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000100 · wf-form4_153332814950530.xml · nonDerivative · entry 1 Bruno Lawrence · CIK 0001730336 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.